News

The EA will assess plant operation, macrolide branded generics and active pharmaceutical ingredients (API) production. The company should abide by regulatory guidelines in terms of surface and ground

The Proteus series of Proton Therapy solutions offer radiotherapy with fewer clinical consequences and is expected to treat 250 to 2,000 patients annually with protons. The solution comprises

At its new site, Diagnovus will develop diagnostic tests and offer information about rare forms of cancer, including pediatric cancers to physicians, payers, patients and families. The new

G-Zero will use the award to continue studies towards ‘Organismal Radioprotection through Pharmacological Quiescence’. Previously in late 2009, the company has also received $0.6m through a phase I

Under the agreement, Lundbeck and Proximagen will jointly apply their expertise in CNS drug development. As part of the agreement, a steering committee involving experts from both companies

The double blind, placebo controlled Phase III ATLAS ACS TIMI 51 clinical trial showed a reduction in cardiovascular death, myocardial infarction and stroke in patients with ACS, compared

The trial, TR701-113 will study the possibility of switching tedizolid phosphate as a once-daily intravenous (IV) infusion to once-daily oral therapy in ABSSSI patients. The 113 study in

The equity funding package comprising private placement will raise a total of $1,951,369.33 by way of a placement of Allied Healthcare shares to investors and related parties of

Selumetinib, a small molecule MEK inhibitor, is an anti-cancer drug in Phase 2 development in a range of tumors. It was licensed from Array to AstraZeneca. The study